According to a report by China Daily on January 25, 2026
Conditional approval highlights China’s growing role in innovative biopharma and global liver disease therapies
China’s National Medical Products Administration (NMPA) has granted conditional approval to Huahui Health’s Libevitug injection, a monoclonal antibody for treating chronic hepatitis D virus (HDV) infection in adults. The therapy can be used in patients with or without compensated cirrhosis, filling a long-standing treatment gap for one of the most severe forms of viral hepatitis.
Libevitug works by blocking hepatitis B and D viruses from entering liver cells, targeting the PreS1 domain of the viral envelope. Chronic HDV, a “defective” virus that requires HBV to replicate, accelerates liver disease progression, increasing risks of cirrhosis and liver cancer. According to the World Health Organization, about 12 million people worldwide with chronic hepatitis B are also co-infected with HDV.
Key Context
Clinical trials showed significant improvements in viral response, liver enzyme normalization, and liver stiffness reduction. At 48 weeks, the combined response rate reached 44.1%, with a virological response rate of 60%.
international regulatory recognition.
Approval aligns with broader national priorities to enhance innovative drug development and improve treatment options for serious liver diseases.
Investor Takeaways
Short-term: Biopharma investors may view Huahui Health and related innovative therapeutics as high-growth opportunities in China’s fast-expanding market.
Medium-term: Conditional approval demonstrates China’s regulatory system is increasingly aligned with global standards, providing clearer pathways for innovative drugs to enter both domestic and international markets.
Strategic insight: The approval signals China’s growing leadership in next-generation biologics, particularly monoclonal antibodies for rare or difficult-to-treat diseases, potentially influencing cross-border partnerships, licensing, and M&A activity.